Continue reading here: USAN Approves Generic Name “Ruxoprubart” for NM8074, an Antibody Therapy focused on Complement-Mediated Diseases
Continue reading here: USAN Approves Generic Name “Ruxoprubart” for NM8074, an Antibody Therapy focused on Complement-Mediated Diseases
Read the original: Artelo Biosciences Announces Selection of Worldwide Clinical Trials as Clinical Research Organization to Support First-in-Human Study of ART26.12
See the article here: Yield10 Bioscience Files Request for Regulatory Status Review with USDA-APHIS for Camelina Designed to Produce the EPA and DHA Components of Omega-3...
Read more: Evaxion Announces Plan to Implement ADS Ratio Change
See more here: Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit
View original post here: Cytek Biosciences Announces Preliminary Full Year 2023 Revenue Results
See the original post: PharmAla-1 Molecule Receives US Patent Prosecution Highway Acceptance
Follow this link: Kriya Provides Update on Pipeline Progress Ahead of Company Presentation at 42nd Annual J.P. Morgan Healthcare Conference
Go here to read the rest: Apellis Announces Preliminary Fourth Quarter and Full Year 2023 U.S. Net Product Revenues
Excerpt from: Scilex Holding Company Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2023 Accomplishments and Outlook for 2024
Recent Comments